The discovery 110 years ago that crude kidney extract elicited a pressor reaction provided the first evidence of the existence of the renin–angiotensin–aldosterone system, a major vasoactive system,1 and the complex actions and interactions of this important cascade are still unfolding. Over the past few decades, various components of the renin−angiotensin−aldosterone system have been elucidated more completely, and previously unknown members have been discovered.2 Drugs that specifically block various components of the renin−angiotensin−aldosterone system have been developed (Figure 1). Angiotensin-converting–enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II, and clinically available angiotensin-receptor blockers block the angiotensin II . . .
Read full abstract